Inovio Pharmaceuticals reported a net loss of $6.0 million ($0.07 per share) for the quarter ended June 30, 2026, compared to a $23.5 million loss in the prior year period, driven by a $13.9 million non-cash gain on warrant liabilities. Operating expenses decreased to $18.6 million from $23.1 million as R&D and G&A costs declined. The company raised approximately $18.3 million net proceeds from an underwritten public equity offering in July 2026, bringing total cash resources to $36.7 million at quarter-end. Regulatory progress includes the FDA review of the BLA for INO-3107 targeting a PDUFA date of October 30, 2026, and positive Phase 3 results for partner VGX-3100 in China. The company anticipates its current cash position will fund operations into late Q1 2027. Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing DNA medicines to treat HPV-related diseases, cancer, and infectious diseases.

Inovio Pharmaceuticals entered into an underwriting agreement on July 29, 2026, to sell 21,052,632 shares of common stock and accompanying warrants in a public offering. The securities were priced at $0.95 per share and warrant combination, with the warrants exercisable for two additional shares at $1.10 per share. Gross proceeds are expected to be approximately $20.0 million, netting roughly $18.3 million after underwriting discounts and expenses. The company granted Piper Sandler & Co. a 30-day option to purchase up to 15% additional securities, which was exercised for warrants only. Closing is anticipated on or about July 31, 2026. Inovio Pharmaceuticals operates in the biotechnology industry, focusing on developing and commercializing DNA medicines.

Inovio Pharmaceuticals disclosed preliminary unaudited cash and cash equivalents of approximately $36.7 million as of June 30, 2026. This figure is based on management estimates and has not been audited or reviewed by Ernst & Young LLP. The company cautioned that actual results may differ materially from these preliminary figures pending the completion of financial closing procedures. Inovio Pharmaceuticals operates in the biotechnology industry, focusing on DNA-based vaccine development.